Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401421 · ClinicalTrials.gov registry record
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
A clinical trial of Breast Cancer, sponsored by Exact Sciences Corporation.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 20
- Study locations
NCT06401421: Recruiting study of Breast Cancer, sponsored by Exact Sciences Corporation.
NCT06401421 is a study of Breast Cancer that is actively recruiting participants, run by Exact Sciences Corporation. The registered enrollment target is 1,800 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401421, a study of Breast Cancer, is actively recruiting participants, sponsored by Exact Sciences Corporation.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ctDNA MRD test
Study Locations (20)
Maryland
- Weinberg Center at Mercy - Baltimore
- Greater Baltimore Medical Center - Baltimore
- Sinai Hospital of Baltimore - Baltimore
- MedStar Georgetown Cancer Institute - Baltimore
- The Center for Cancer and Blood Disorders - Bethesda - Bethesda
Florida
- AdventHealth East Altamonte Oncology and Hematology - Altamonte Springs
- Mount Sinai Medical - Comprehensive Cancer Center - Miami Beach
- Baptist Cancer Care - Plantation - Plantation
- St. Joseph's Women's Hospital - Tampa
California
- Stanford Cancer Institute - Palo Alto
- Harbor-UCLA Medical Center - Hematology / Oncology - Torrance
- Kaiser Permanente Medical Center - Vallejo
Kentucky
- St. Elizabeth Edgewood Hospital - Edgewood
- Norton Cancer Institute - Downtown - Louisville
- Baptist Health Louisville - Louisville
Alaska
- Katmai Oncology Group - Anchorage - Anchorage
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center - Aurora
Illinois
- Rush Cancer Center - Chicago
Indiana
- Deaconess Chancellor Center for Oncology - Newburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2030-04 |
What NCT06401421 shows while recruiting
NCT06401421 is an observational study that tracks outcomes without assigning an intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ctDNA MRD test is the first listed.
NCT06401421 names 20 study sites across 9 states, led by Maryland, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06401421 about?
NCT06401421 is a clinical study titled "EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)". The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
What is the current status of trial NCT06401421?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2024-06-07. Estimated completion is 2030-04.
What conditions does trial NCT06401421 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06401421?
The interventions under investigation include: ctDNA MRD test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06401421?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401421 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06401421's enrollment target sits among peer trials
1,800 74th of 1224 higher than 1,149 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI